Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...

Weight loss drugs may have more benefits than some realize.According to a new observational study by St. Luke’s Mid-America ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

Supplements to reduce cortisol have been rising in popularity. They claim to lower stress levels. Are they legit?